MedPath

Prospective Post Approval Clinical Follow-Up Study of the Commercially Available U2 Knee™ System - "U-Propel Study"

Active, not recruiting
Conditions
Osteo Arthritis Knee
Registration Number
NCT03060057
Lead Sponsor
United Orthopedic Corporation
Brief Summary

The purpose of this study is to evaluate both short and long term clinical performance and safety of the commercially available U2 Knee™ System.

Detailed Description

This is a prospective, single arm, multi-center, post-approval study designed to evaluate the short and long term clinical performance and safety in subjects receiving primary total knee arthroplasty (TKA) with the U2 Knee™ System. The study will enroll up to 200 subjects with scheduled pre-discharge, 6-week, 3- and 6-month and up to 5-year annual follow-up visits. Study outcomes will be analyzed and published when 1.) all enrolled and implanted subjects complete their 6-week follow up, 2.) all implanted subjects complete their 2-year follow up, 3.) at the conclusion of the study.

The study will follow GCP guidelines and will be registered on clinicaltrials.gov.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  1. Subject is between 18 and 75 years of age
  2. Subject is indicated for a unilateral total knee arthroplasty (TKA) based on the approved labeling of the device
  3. Subject has no history of previous prosthetic replacement device or orthopedic surgeries on the operative knee
  4. Subject is willing and able to provide informed consent to participate in the study;
  5. Subject is willing and able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits;
Exclusion Criteria
  • Subjects will be excluded if, in the opinion of the Investigator, the subject does not qualify based on approved labeling requirements or Subject Inclusion criteria.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Implant Survivorship2 Years

Device Survivorship defined as no revision of removal of any parts of the system

Secondary Outcome Measures
NameTimeMethod
Change in EQ-5D Over TimeBaseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 3 years, 4 years, 5 years

This endpoint is defined as differences in scores related to the EQ-5D questionnaire and the EQ-VAS measured at current and pre-discharge visits.

Change in EQ-5D VAS Over TimeBaseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 3 years, 4 years, 5 years

This endpoint is defined as differences in scores related to the EQ-5D VAS questionnaire and the EQ-VAS measured at current and pre-discharge visits.

Radiographic Analysis24 months, 5 years

This endpoint is defined as incidence rate of new radiographic failures at each follow-up visit.

Subject Satisfaction Survey6 weeks, 3 months, 6 months, 12 months, 2 Years, 3 Years, 4 Years and 5 Years.

Subject satisfaction with their knee surgery.

Change in KOOS, JR. Over TimeBaseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 3 years, 4 years, 5 years

This endpoint is defined as difference in the KOOS, Jr interval score measured at current and pre-discharge visits.

Change in Knee Society Score (KSS) Over TimeBaseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 3 years, 4 years, 5 years

This endpoint is defined as differences in both pain and functional parameters measured at current and pre-discharge visits

Operative characteristicsOperative

Descriptive statistics in operative characteristics will be reported as secondary endpoints to evaluate operative success

Trial Locations

Locations (4)

Coastal Orthopedics

🇺🇸

Bradenton, Florida, United States

Jacksonville Orthopaedic Institute

🇺🇸

Jacksonville, Florida, United States

Orthopedic Center of Vero Beach

🇺🇸

Vero Beach, Florida, United States

Rubin Institute for Advanced Orthopedics

🇺🇸

Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath